Regarding ROS1-dependent mechanisms of acquired resistance, ROS1 secondary point mutations (G2032R, D2033N, L2026M, S1986F/Y) occur in approximately 50−60% of crizotinib resistant NSCLC cases [47]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.